{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:30Z","timestamp":1790186550390,"version":"4.1.0"},"reference-count":118,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Optogenetics, a cutting-edge tool in novel gene manipulation and drug discovery, holds significant therapeutic potential for a variety of neurological disorders, including retinal diseases. Retinal diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), significantly impair quality of life and cause severe visual impairment due to limited treatment options and a general lack of awareness. The increasing incidence of these degenerative conditions underscores the need for innovative solutions, such as optogenetics. Optogenetic therapy introduces genes coding for light-sensitive proteins, which are controlled by light signals to make neurons photosensitive. This precise targeting approach does not require specific gene intervention and can bypass dysfunctional photoreceptors, offering a treatment option for various degenerative and dystrophic eye diseases. Successful outcomes in patients with late-stage genetic retinal diseases and numerous clinical trials suggest that optogenetics could be an effective treatment for humans. This review provides an overview of the current landscape of optogenetic therapy, discusses its challenges, and summarizes the findings of ongoing clinical trials for neural and visual restoration.<\/jats:p>","DOI":"10.1177\/11206721251335560","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:42:26Z","timestamp":1745206946000},"page":"1901-1920","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Optogenetic therapy for retinal degenerative diseases: A review"],"prefix":"10.1177","volume":"35","author":[{"given":"Ehab","family":"Kasem","sequence":"first","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, Damascus University, Almwasat Hospital, Damascus, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masa","family":"Watfa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, Tishreen University Hospital, Lattakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afif","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tishreen University, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Hasan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tishreen University, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3962-9156","authenticated-orcid":false,"given":"Majd","family":"Mansour","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tishreen University, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Almhmoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tishreen University, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-709X","authenticated-orcid":false,"given":"Basem","family":"Zaino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tishreen University Hospital, Lattakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1430136"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021120"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftale.2023.08.008"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-95046-4_26"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","DOI":"10.3390\/genes12081261","article-title":"Leber\u2019s congenital amaurosis: current concepts of genotype-phenotype correlations","volume":"12","author":"Huang CH","year":"2021","unstructured":"Huang CH, Yang CM, Yang CH, et al. Leber\u2019s congenital amaurosis: current concepts of genotype-phenotype correlations. Genes (Basel) 2021; 12: 11\u201312.","journal-title":"Genes (Basel)"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.10.008"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2021.01.003"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0792"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2023.101582"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05477-6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e328363829b"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom12020269"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000140"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr2111915"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/newbio233149a0"},{"key":"e_1_3_3_17_2","unstructured":"Anna Vlasits. He may have invented one of neuroscience\u2019s biggest advances. But you\u2019ve never heard of him. STAT News https:\/\/www.statnews.com\/2016\/09\/01\/optogenetics\/ (2016 accessed 4 May 2024)."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3410\/B3-11"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2019.00466","article-title":"Optogenetics: background, methodological advances and potential applications for cardiovascular research and medicine","volume":"7","author":"Joshi J","year":"2020","unstructured":"Joshi J, Rubart M, Zhu W. Optogenetics: background, methodological advances and potential applications for cardiovascular research and medicine. Front Bioeng Biotechnol 2020; 7: 1\u20132.","journal-title":"Front Bioeng Biotechnol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.15"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3111"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2022.05.014"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03597-6"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2016.00074","article-title":"Biophysical properties of optogenetic tools and their application for vision restoration approaches","volume":"10","author":"Klapper SD","year":"2016","unstructured":"Klapper SD, Swiersy A, Bamberg E, et al. Biophysical properties of optogenetic tools and their application for vision restoration approaches. Front Syst Neurosci 2016; 10: 1\u201311.","journal-title":"Front Syst Neurosci"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.09.030186.000511"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1979.sp012716"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2142\/biophysico.12.0_121"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1241903"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4091"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.12.004"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1936192100"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2008.11.034"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2009.051961"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2117"},{"key":"e_1_3_3_35_2","article-title":"Chr2 mutants at L132 and T159 with improved operational light sensitivity for vision restoration","volume":"9","author":"Pan Z-H","year":"2014","unstructured":"Pan Z-H, Ganjawala TH, Lu Q, et al. Chr2 mutants at L132 and T159 with improved operational light sensitivity for vision restoration. PLoS One 2014; 9: e98924.","journal-title":"PLoS One"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01351-4"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194947"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth0914-972"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.09.014"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905852106"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3752"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101089","article-title":"Optogenetics for visual restoration: from proof of principle to translational challenges","volume":"91","author":"Lindner M","year":"2022","unstructured":"Lindner M, Gilhooley MJ, Hughes S, et al. Optogenetics for visual restoration: from proof of principle to translational challenges. Prog Retin Eye Res 2022; 91: 2\u201316.","journal-title":"Prog Retin Eye Res"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701589114"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-017-0475-2"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2016.03.007"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01761"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2005.04.063"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.07.016"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.03.003"},{"key":"e_1_3_3_50_2","first-page":"5768","article-title":"Human opsin-G-protein fusion proteins as potential light sensitizers","volume":"55","author":"Hickey D","year":"2014","unstructured":"Hickey D, Hughes S, Davies WL, et al. Human opsin-G-protein fusion proteins as potential light sensitizers. Invest Ophthalmol Vis Sci 2014; 55: 5768\u20135768.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2015.07.029"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09124-x"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4014797"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15317-6"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22473"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002143"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111515"},{"key":"e_1_3_3_58_2","first-page":"2020.09.17.3015","article-title":"High-sensitivity vision restoration via ectopic expression of chimeric rhodopsin in mice","author":"Katada Y","year":"2022","unstructured":"Katada Y, Yoshida K, Serizawa N, et al. High-sensitivity vision restoration via ectopic expression of chimeric rhodopsin in mice. bioRxiv 2022; 26: 2020.09.17.301523.","journal-title":"bioRxiv"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-00200-2"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16823"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201900485"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00287-1"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara D","year":"2013","unstructured":"Dalkara D, Byrne LC, Klimczak RR, et al. In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013; 5: 8.","journal-title":"Sci Transl Med"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.03.003"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020147"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15230"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00394-1"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12530"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10258"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.028"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5"},{"key":"e_1_3_3_72_2","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl HCJ","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol 2022; 13: 6.","journal-title":"Front Immunol"},{"key":"e_1_3_3_73_2","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au HKE","year":"2022","unstructured":"Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med (Lausanne) 2022; 8: 5\u201310.","journal-title":"Front Med (Lausanne)"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2019.107433"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.098"},{"key":"e_1_3_3_76_2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore ZC","year":"2020","unstructured":"Elmore ZC, Oh DK, Simon KE, et al. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight 2020; 5: 1\u20136.","journal-title":"JCI Insight"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2283"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00021.2004"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.01.024"},{"key":"e_1_3_3_80_2","article-title":"Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells","volume":"111","author":"Gaub BM","year":"2014","unstructured":"Gaub BM, Berry MH, Holt AE, et al. Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc Natl Acad Sci USA 2014; 111: 1\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190897"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.09.003"},{"key":"e_1_3_3_83_2","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.648210","article-title":"Control of microbial opsin expression in stem cell derived cones for improved outcomes in cell therapy","volume":"15","author":"Garita-Hernandez M","year":"2021","unstructured":"Garita-Hernandez M, Chaffiol A, Guibbal L, et al. Control of microbial opsin expression in stem cell derived cones for improved outcomes in cell therapy. Front Cell Neurosci 2021; 15: 7\u201310.","journal-title":"Front Cell Neurosci"},{"key":"e_1_3_3_84_2","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-01594-w","article-title":"Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates","volume":"4","author":"Gauvain G","year":"2021","unstructured":"Gauvain G, Akolkar H, Chaffiol A, et al. Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. Commun Biol 2021; 4: 1\u20137.","journal-title":"Commun Biol"},{"key":"e_1_3_3_85_2","unstructured":"GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment \u2013 GenSight Biologics https:\/\/www.gensight-biologics.com\/2021\/11\/17\/gensight-biologics-reports-second-patient-case-showing-significant-visual-recovery-after-gs030-optogenetic-treatment\/ (accessed 12 May 2024)."},{"key":"e_1_3_3_86_2","unstructured":"Study Details | Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03326336?rank=1 (accessed 6 October 2024)."},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1117\/1.NPh.4.4.049801"},{"key":"e_1_3_3_88_2","unstructured":"Hutton D. Optogenetic gene therapy restores vision in 11 RP patients https:\/\/www.ophthalmologytimes.com\/view\/optogenetic-gene-therapy-restores-vision-in-11-rp-patients (2021 accessed 12 May 2024)."},{"key":"e_1_3_3_89_2","unstructured":"Study Details | A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05921162 (accessed 6 October 2024)."},{"key":"e_1_3_3_90_2","unstructured":"Allen C. Ho. MCO-010 optogenetic gene therapy for severe vision loss in Stargardt disease https:\/\/www.modernretina.com\/view\/mco-010-optogenetic-gene-therapy-for-severe-vision-loss-in-stargardt-disease (2023 accessed 12 May 2024)."},{"key":"e_1_3_3_91_2","unstructured":"Study Details | Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05417126 (accessed 6 October 2024)."},{"key":"e_1_3_3_92_2","unstructured":"Study Details | Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06048185 (accessed 6 October 2024)."},{"key":"e_1_3_3_93_2","unstructured":"Study Details | Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04945772 (accessed 6 October 2024)."},{"key":"e_1_3_3_94_2","unstructured":"Study Details | Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06162585 (accessed 6 October 2024)."},{"key":"e_1_3_3_95_2","unstructured":"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis Exudation and Degeneration Meeting - Nanoscope Therapeutics https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/ (2024 accessed 12 May 2024)."},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1117\/1.NPh.5.2.025009"},{"key":"e_1_3_3_97_2","unstructured":"The neural code that could help treat blindness https:\/\/www.nbcnews.com\/mach\/video\/cracking-the-code-to-treat-blindness-1385480259560 (2019 accessed 12 May 2024)."},{"key":"e_1_3_3_98_2","unstructured":"Bionic Sight Reports Meaningful Vision Improvements for RP Patients Receiving Highest Dose of its Emerging Optogenetic Therapy \u2014 Foundation Fighting Blindness https:\/\/www.fightingblindness.org\/research\/bionic-sight-reports-meaningful-vision-improvements-for-rp-patients-receiving-highest-dose-of-its-emerging-optogenetic-therapy-281 (2023 accessed 12 May 2024)."},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2018.09.003"},{"key":"e_1_3_3_100_2","unstructured":"Study Details | EyeConic: Qualification for Cone-Optogenetics | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05294978 (accessed 6 October 2024)."},{"key":"e_1_3_3_101_2","unstructured":"Study Details | Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06292650 (accessed 6 October 2024)."},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315041"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1109\/TBCAS.2019.2951298"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69740-7"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523218666180302163814"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0872-18.2018"},{"key":"e_1_3_3_107_2","doi-asserted-by":"crossref","DOI":"10.1088\/1741-2552\/ac6061","article-title":"Co-expressing fast channelrhodopsin with step-function opsin overcomes spike failure due to photocurrent desensitization in optogenetics: a theoretical study","volume":"19","author":"Bansal H","year":"2022","unstructured":"Bansal H, Pyari G, Roy S. Co-expressing fast channelrhodopsin with step-function opsin overcomes spike failure due to photocurrent desensitization in optogenetics: a theoretical study. J Neural Eng 2022; 19: 1\u201316.","journal-title":"J Neural Eng"},{"key":"e_1_3_3_108_2","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.10.6.10","article-title":"Optogenetic modulation of intraocular pressure in a glucocorticoid-induced ocular hypertension mouse model","volume":"10","author":"Kowal TJ","year":"2021","unstructured":"Kowal TJ, Prosseda PP, Ning K, et al. Optogenetic modulation of intraocular pressure in a glucocorticoid-induced ocular hypertension mouse model. Transl Vis Sci Technol 2021; 10: 3\u20134.","journal-title":"Transl Vis Sci Technol"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2022.0290"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00399-017-0545-8"},{"key":"e_1_3_3_111_2","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.61.10.44","article-title":"Optogenetic stimulation of cholinergic amacrine cells improves capillary blood flow in diabetic retinopathy","volume":"61","author":"Ivanova E","year":"2020","unstructured":"Ivanova E, Bianchimano P, Corona C, et al. Optogenetic stimulation of cholinergic amacrine cells improves capillary blood flow in diabetic retinopathy. Invest Ophthalmol Vis Sci 2020; 61: 11.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1437138"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(03)00039-9"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2015.140"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1113\/JP282076"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0121"},{"key":"e_1_3_3_117_2","article-title":"Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene therapy","author":"Ford JL","unstructured":"Ford JL, Karatza E, Mody H, et al. Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene therapy. Clin Pharmacol Ther 2024; 115: 1212.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.08.004"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108196"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251335560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251335560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251335560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:41:13Z","timestamp":1777405273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251335560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/11206721251335560"],"URL":"https:\/\/doi.org\/10.1177\/11206721251335560","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}